CHRM3

Muscarinic acetylcholine receptor M3 · P20309 · CHRM3 on Sugi Atlas →

412,380 patent compounds predicted against CHRM3, 230,796 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL33238	0.58	20/20
SCHEMBL33239	0.58	20/20
Dimethindene (SCHEMBL18759)	1.00	19/20
Mazaticol (SCHEMBL34619)	0.51	19/20
Tiotropium (SCHEMBL4589)	1.00	17/20
Tiotropium (SCHEMBL8625)	1.00	17/20
Clemastine (SCHEMBL33403)	0.84	14/20
Trospium (SCHEMBL25785)	1.00	12/20
Diphenidol (SCHEMBL34469)	1.00	12/20
Fenpiverinium (SCHEMBL23654)	0.53	12/20
Oxapium (SCHEMBL24857)	0.41	10/20
Tolterodine (SCHEMBL3064)	1.00	9/20
Tolterodine (SCHEMBL36881)	1.00	9/20
Tolterodine (SCHEMBL36882)	1.00	9/20
Carbamoylcholine (SCHEMBL2792)	1.00	8/20
Acetylcholine (SCHEMBL3216)	1.00	8/20
Clemastine (SCHEMBL4178)	1.00	8/20
Drofenine (SCHEMBL25124)	0.63	7/20
Cyclandelate (SCHEMBL5123)	0.54	7/20
Oxotremorine (SCHEMBL2128)	1.00	6/20

Clinical trials — most relevant to CHRM3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD	PHASE4	COMPLETED
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia	PHASE4	COMPLETED
Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications	PHASE4	COMPLETED
Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause	PHASE4	COMPLETED
Galantamine for Cognition in People With Schizophrenia	PHASE4	COMPLETED
Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD	PHASE3	COMPLETED
Metoclopramide as Treatment of Clozapine-induced Hypersalivation	PHASE3	COMPLETED
A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma	PHASE2	COMPLETED
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease	PHASE1/PHASE2	RECRUITING
24hr Effects of Tiotropium Bromide in Tetraplegia	PHASE2	COMPLETED
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Nicotinic Receptors and Schizophrenia	PHASE1/PHASE2	WITHDRAWN
Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia	PHASE2	COMPLETED
A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS	PHASE2	RECRUITING
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)	PHASE2	COMPLETED
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition	PHASE2	RECRUITING
A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants	PHASE1	NOT_YET_RECRUITING
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care	PHASE1	COMPLETED
M1 Schizophrenia PET Study	PHASE1	COMPLETED
Cholinergic Mechanisms of Attention in Aging	EARLY_PHASE1	COMPLETED
Development of Cognitive Assessment Tools in Parkinson Disease	EARLY_PHASE1	COMPLETED
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy	nan	COMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine	nan	WITHDRAWN
Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers	nan	UNKNOWN
Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome	nan	COMPLETED
Mental Ability Challenge Study in Adults With and Without HIV	nan	COMPLETED
Cholinergic Status and the Metabolic Syndrome	nan	UNKNOWN
Sjogren's Lung Study	nan	SUSPENDED
Effect of Mirabegron on Bladder Compliance	nan	UNKNOWN
Effectiveness of Bryophyllum in Nocturia-Therapy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRM3 binder may also engage these)

Protein	Name	Similarity
Q9N2A4	—	1.000	Q9N2A4 →
P08483	—	1.000	P08483 →
P11483	—	1.000	P11483 →
Q9N2A3	—	1.000	Q9N2A3 →
P41984	—	1.000	P41984 →
Q9ERZ3	—	1.000	Q9ERZ3 →
Q9N2A2	—	1.000	Q9N2A2 →
Q5IS53	—	0.999	Q5IS53 →
P49578	—	0.997	P49578 →
CHRM5	Muscarinic acetylcholine receptor M5	0.997	landscape →
P56490	—	0.997	P56490 →
P08911	—	0.994	P08911 →
Q5IS98	—	0.994	Q5IS98 →
P70174	—	0.994	P70174 →
Q18007	—	0.993	Q18007 →
Q920H4	—	0.992	Q920H4 →
Q9U7D5	—	0.991	Q9U7D5 →
Q09388	—	0.989	Q09388 →
Q75Z89	—	0.988	Q75Z89 →
HRH1	Histamine H1 receptor	0.987	landscape →
HTR2C	5-hydroxytryptamine receptor 2C	0.987	landscape →
P31390	—	0.987	P31390 →
P18599	—	0.986	P18599 →
Q4LBB9	—	0.985	Q4LBB9 →
O46635	—	0.985	O46635 →
Q02152	—	0.984	Q02152 →
Q8UUG8	—	0.984	Q8UUG8 →
Q6TLI9	—	0.984	Q6TLI9 →
Q5IS66	—	0.983	Q5IS66 →
Q9N2B2	—	0.983	Q9N2B2 →